Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options

Area of Science:

• Gynecological Oncology
• Cancer Pharmacology
• Molecular Biology

Background:

• Ovarian cancer is a leading cause of cancer death, often diagnosed at advanced stages.
• Treatment failure is frequently due to acquired drug resistance, leading to relapse and mortality.
• Current therapies including carboplatin, paclitaxel, polyadenosine diphosphate ribose polymerase (PARP) inhibitors, and bevacizumab face limitations from resistance.

Purpose of the Study:

• To review and analyze the molecular mechanisms underlying resistance to key ovarian cancer drugs.
• To provide an in-depth understanding of how cancer cells evade treatment.
• To highlight the importance of this knowledge for future therapeutic strategies.

Main Methods:

• Literature review and analysis of extensively investigated resistance mechanisms.
• Detailed examination of molecular pathways involved in drug resistance.
• Synthesis of current knowledge on drug inactivation, target alteration, efflux pumps, DNA repair, and drug accumulation.

Main Results:

• Identified key resistance mechanisms: drug inactivation, target alteration, enhanced drug efflux, increased DNA repair, and reduced drug uptake.
• Detailed the molecular basis for resistance to carboplatin, paclitaxel, PARP inhibitors, and bevacizumab.
• Highlighted the heterogeneity of resistance mechanisms in ovarian cancer.

Conclusions:

• Understanding molecular resistance mechanisms is critical for overcoming treatment failure in ovarian cancer.
• This knowledge can guide the discovery of novel biomarkers for predicting and monitoring resistance.
• Identifying these mechanisms is essential for developing new therapeutic targets to improve patient outcomes.